The following posters will be presented by the investigators from The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital:
Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild Type c-KIT And Potential Impact On Normal Hematopoiesis. Session Name: Molecular Pharmacology, Drug Resistance: Poster III. Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.
The Combination Of FLT3 Inhibition And Hypomethylation Confers Synergistic Antileukemic Effects On FLT3-ITD Positive AML Cell Lines And Primary Cells: Session Name: Acute Myeloid Leukemia: Therapy, excluding Transplantation: Poster III. Presentation on Monday, December 9, 2013 from 6:00 - 8:00 pm in Hall E.
The abstracts and posters can be accessed on the ASH website at http://hematology.org.
Third Quarter Results
Revenues were $7.7 million and $4.3 million for the quarters ended September 30, 2013 and 2012, respectively. The increase of $3.4 million was primarily due to acceleration in the recognition of license fee revenue related to the Company's collaboration with Astellas Pharma. In March 2013, the Company received a notice of termination of the agreement from Astellas, which termination was effective September 2013.
Research and development expenses were $4.5 million and $8.2 million for the quarters ended September 30, 2013 and 2012, respectively. The decrease of $3.7 million was primarily due to lower quizartinib research and development expenses. This resulted from a reduction in the number of patients being treated and followed in our Phase 2 clinical trial, in which enrollment was completed in late 2011.
General and administrative expenses were
|SOURCE Ambit Biosciences|
Copyright©2012 PR Newswire.
All rights reserved